Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (186)	12/7/1999 8:45:00 PM
From: LLCF	Respond to of 395

<NEJM article in the December 9 edition showing no benefit of a single secretin dose in autism. > Amazing to me that anyone would do a study on a single dose... if this is a relevant endpoint the company should save themselves a ton and just sell the stuff off label. JMO of course. DAK

To: Biomaven who wrote (186)	12/7/1999 8:47:00 PM
From: JMarcus	Respond to of 395

Peter, there is plausible speculation on the Yahoo thread that this is really old news of marginal importance: messages.yahoo.com >>This study wasn't really "news" because it's results were announced last summer. It was also bogus because it involved doing only one infusion, and then looking for results. Sort of like oding an exercise program in a gym once, then looking for all that increased muscle strength the next day - I don;t think so. Nearly every time secretin has been reported as beneficial, it has involved more than one infusion. Normally, a series of infusions or transdermal application are used when secretin works well.<< If so, this may be a great opportunity to buy. Marc